KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Esperion Therapeutics (ESPR) Leases (2019 - 2025)

Esperion Therapeutics' Leases history spans 7 years, with the latest figure at $2.9 million for Q4 2025.

  • For Q4 2025, Leases fell 47.0% year-over-year to $2.9 million; the TTM value through Dec 2025 reached $2.9 million, down 47.0%, while the annual FY2025 figure was $2.9 million, 47.0% down from the prior year.
  • Leases reached $2.9 million in Q4 2025 per ESPR's latest filing, down from $3.3 million in the prior quarter.
  • In the past five years, Leases ranged from a high of $7.1 million in Q1 2024 to a low of $730000.0 in Q3 2022.
  • Average Leases over 5 years is $3.6 million, with a median of $3.5 million recorded in 2021.
  • Peak YoY movement for Leases: plummeted 80.35% in 2022, then soared 563.26% in 2024.
  • A 5-year view of Leases shows it stood at $1.9 million in 2021, then crashed by 45.42% to $1.0 million in 2022, then soared by 351.25% to $4.7 million in 2023, then rose by 17.93% to $5.5 million in 2024, then plummeted by 47.0% to $2.9 million in 2025.
  • Per Business Quant, the three most recent readings for ESPR's Leases are $2.9 million (Q4 2025), $3.3 million (Q3 2025), and $4.2 million (Q2 2025).